Company Sponsored Sessions

​​Thursday, May 4, 2017

​13:15 - Pipeline Session. More information coming soon

Effective management of disease-related cytopenias and associated risks in patients with MDS

4 May 2017, 19:30–20:30, Auditorium 3

Programme chair: 
Dr John Porter

Dr Uwe Platzbecker, Dr Pierre Fenaux

Welcome and introductions
John Porter

Do thrombopoietin-receptor agonists have a role in the treatment of thrombocytopenia in MDS patients?
Pierre Fenaux

Iron overload as a potential risk factor in the setting of allogeneic HSCT
Uwe Platzbecker

Beyond iron removal: clinical benefits of iron chelation therapy in patients with lower-risk MDS
John Porter

Q&A and meeting close
Moderated by John Porter


  • Discuss cytopenias in myelodysplastic syndromes (MDS), with a focus on symptomatic anemia and thrombocytopenia, clinical symptoms, and prognostic relevance
  • Report on the current approaches for the management of anemia (red blood cell [RBC] transfusions) and thrombocytopenia (platelet transfusions, use of growth factors and thrombopoietin receptor agonists [TPO-RAs]), including the consequences of repeated transfusions such as iron overload and risk of infection and the unmet medical needs
  • Discuss the use and controversial clinical data relating to TPO-RAs in patients with MDS of different risk categories
  • Provide insights into the use of iron chelation therapy in lower-risk MDS patients with RBC transfusion dependence, based on clinical experience and from an evidence-based perspective
  • Discuss unmet medical needs and report the latest clinical trial data from investigational treatments that may decrease transfusion requirements
  • Review early considerations for MDS patients who are potential candidates for hematopoietic stem cell transplantation (HSCT)

Friday, May 5, 2017

13:45 - More information coming soon

Keep Me Updated